MS4A1 and systemic sclerosis: Given the high level of auto-antibodies and the presence of B cell infiltrates in skin samples of SSc patients, Rituximab (anti-CD20), which depletes B cells, has been recently tested with some success, especially in CYC refractory patients (Fernández-Codina et al., 2018; Elhai et al., 2019).